πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12358968

Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treat

Providence Health & Servicesβ€”Oregon Β· Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12357598

Treatment of neurodevelopmental disorders

The Regents of the University of California Β· Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12358971

Arena virus monoclonal antibodies and uses

The Boad of Regents of the University of Texas System Β· Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12358921

Antiviral heterocyclic compounds

Enanta Pharmaceuticals, Inc. Β· Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12357616

Methods of treating multiple sclerosis

VANDA PHARMACEUTICALS INC. Β· Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12357615

Compositions for the treatment of brain tumors

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12358931

3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabi

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12357604

Topical formulations of cannabinoids and use thereof in the treatment of pain

INMED PHARMACEUTICALS INC. Β· Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12357623

Method for treating a disease or condition using a pyrazole compound or formulation thereo

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351614

CLEC9A-based chimeric protein complexes

Orionis Biosciences, Inc Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351625

Therapeutic antibodies against osteopontin

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351633

PD-1 and PD-L1 binding agents

Orionis Biosciences, Inc Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351590

Pyrrolopyrimidine compound and use thereof

Medshine Discovery Inc. Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351574

Selective ligands for modulation of GIRK channels

Northwestern University Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351579

Compounds and uses thereof

FOGHORN THERAPEUTICS INC. Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351638

Chimeric antigen receptors targeting BCMA and methods of use thereof

LEGEND BIOTECH USA INC. Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351581

Compounds for FGFR inhibition

Cogent Biosciences, Inc. Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351587

Bicyclic compound as RIP-1 kinase inhibitor and application thereof

Medshine Discovery Inc. Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12350383

Cationic lipids containing silicon

ARBUTUS BIOPHARMA CORPORATION Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351644

Anti-CD73 antibodies

Corvus Pharmaceuticals, Inc. Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351561

Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hyd

Theravance Biopharma R&D IP, LLC Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351611

Molecules for organelle-specific protein delivery

Larimar Therapeutics, Inc. Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351653

Pharmaceutical compositions comprising novel cyclic peptides

LISATA THERAPEUTICS, INC. Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12351824

Method for producing natural killer cells from pluripotent stem cells

Takeda Pharmaceutical Company Limited Β· Granted Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted